|Application ||WB, E|
|Other Accession||B2RYN2, Q3TQF0, NP_079011.3|
|Calculated MW||60664 Da|
|Antigen Region||310-338 aa|
|Other Names||F-box only protein 31, FBXO31, FBX14, FBX31|
|Target/Specificity||This FBXO31 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 310-338 amino acids from the Central region of human FBXO31.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||FBXO31 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Component of some SCF (SKP1-cullin-F-box) protein ligase complex that plays a central role in G1 arrest following DNA damage. Specifically recognizes phosphorylated cyclin-D1 (CCND1), promoting its ubiquitination and degradation by the proteasome, resulting in G1 arrest. May act as a tumor suppressor.|
|Tissue Location||Highly expressed in brain. Expressed at moderate levels in most tissues, except bone marrow|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Members of the F-box protein family, such as FBXO31, are characterized by an approximately 40-amino acid F-box motif. SCF complexes, formed by SKP1 (MIM 601434), cullin (see CUL1; MIM 603134), and F-box proteins, act as protein-ubiquitin ligases. F-box proteins interact with SKP1 through the F box, and they interact with ubiquitination targets through other protein interaction domains (Jin et al., 2004 [PubMed 15520277]).[supplied by OMIM].
Rivadeneira, F., et al. Nat. Genet. 41(11):1199-1206(2009)
Santra, M.K., et al. Nature 459(7247):722-725(2009)
Kumar, R., et al. Cancer Res. 65(24):11304-11313(2005)
Jin, J., et al. Genes Dev. 18(21):2573-2580(2004)
Powell, J.A., et al. Genomics 80(3):303-310(2002)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.